Axis-Shield gives revenue warning over flu impact
This article was originally published in Clinica
Executive Summary
UK diagnostics expert Axis-Shield has missed revenue expectations after a mild flu season led to a decline in sales of its NycoCard C-reactive protein (CRP) test.